BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .
RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President of BDSI, will present at the Oppenheimer 28th Annual Healthcare Conference.
Presentation Details:Date: Tuesday, March 20, 2018
Time: 3:55 PM Eastern Time
Location: The Westin New York Grand CentralMr. Plesha will focus on continued progress with commercialization efforts supporting BELBUCA® (buprenorphine) buccal film (CIII) following strong sales growth in 2017. Mr. Plesha will also review the expanded sales effort as well as new managed care coverage for BELBUCA® that is expected to continue to support BELBUCA® sales growth in 2018 and beyond.The presentation will be webcast live and can be accessed in the investor section (events page) of the BDSI website. For those who are not available to listen to the live broadcast, a replay of the webcast will be available.About BioDelivery Sciences International, Inc.BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI’s headquarters is in Raleigh, North Carolina. For more information, please visit or follow us:Internet: www.bdsi.com
Twitter: @BioDeliverySIBUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.Cautionary Note on Forward-Looking StatementsThis press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI’s management and are subject to significant risks and uncertainties, including those detailed in the BDSI’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA and BUNAVAIL based on the products attributes described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI’s control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.© 2018 BioDelivery Sciences International, Inc. All rights reserved.Contacts
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.